Fixed-Duration Ibrutinib Plus Venetoclax Beneficial for Leukemia
Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.